Cancer, Platinum-resistant ovarian cancer, Ovarian cancer
GNLXGenelux CorporationCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Olvi-Vec (Olvimulogene nanivacirepvec) + platinum-doublet + bevacizumab in Cancer, Platinum-resistant ovarian cancer, Ovarian cancer. The expected timing is based on the latest available company guidance and may change.
OnPrime/GOG-3076 trial. 09/2022- Initiated trial. Trial ongoing. 11/27/23- Granted Fast Track Designation. 8/7/25- Topline data in H1 2026. 11/05/25:- Enrollment in the Phase 3 OnPrime ovarian cancer trial remains active; topline data timeline revised with data now expected in H2 2026. 03/19/26:- OnPrime Phase 3 IDMC review Feb 2026 recommended continuation without changes; topline H2 2026 reiterated. 05/07/26:- OnPrime/GOG-3076 Phase 3 trial remains on track; topline ovarian cancer data expected in H2 2026. 08/13/26:- Phase 3 OnPrime/GOG-3076 topline data are expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.